MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

Meeting: 2017 International Congress

Abstract Number: 404

Keywords: Tardive dyskinesia(TD)

Session Information

Date: Tuesday, June 6, 2017

Session Title: Drug-Induced Movement Disorders

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: To evaluate the efficacy of deutetrabenazine (DTB), as measured by the Clinical Global Impression of Change (CGIC), in patients with tardive dyskinesia (TD) from the pooled ARM-TD and AIM-TD (24 and 36 mg/day doses) data sets, as compared with the pooled placebo cohort.

Background: TD is an involuntary movement disorder that is often irreversible and can affect any body region. In the ARM-TD and AIM-TD studies, DTB treatment demonstrated statistically and clinically significant reductions in Abnormal Involuntary Movement Scale (AIMS) scores at Week 12 compared with placebo (primary endpoint). The CGIC is a 7-point Likert scale ranging from “very much worse” to “very much improved” that provides an overall assessment of treatment response, providing insight into a clinician’s view on the change in the patient’s TD symptoms as well as the occurrence of side effects.

Methods: ARM-TD and AIM-TD were 12-week, randomized, double-blind, placebo-controlled studies that evaluated the safety and efficacy of DTB for the treatment of TD. Patients had baseline AIMS scores ≥6. Change in AIMS score from baseline to Week 12 was the primary endpoint of both studies. The key secondary endpoint of each study was the proportion of patients “much improved” or “very much improved” (treatment success) at Week 12 on the CGIC.

Results: At Week 12, the odds of treatment success (“much improved” or “very much improved”) among patients treated with DTB (n=152) was more than double that of patients treated with placebo (n=107; odds ratio: 2.12; P=0.005). In a shift analysis of all CGIC ratings, patients treated with DTB had greater improvement as assessed by clinicians than that observed with placebo (P=0.003). In addition, the mean CGIC score was significantly more improved in patients treated with DTB than in those treated with placebo at Week 12 (treatment difference: –0.4; P=0.006).

Conclusions: DTB treatment led to statistically and clinically significant improvements in TD symptoms based on CGIC results. These results suggest that a global assessment of patients’ clinical status may be useful to assess DTB therapy in clinical practice.

 

Presented at: APA annual meeting; May 20–24, 2017; San Diego, CA, USA

To cite this abstract in AMA style:

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson. Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/improvements-in-clinical-global-impression-of-change-with-deutetrabenazine-treatment-in-tardive-dyskinesia-from-the-arm-td-and-aim-td-studies/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/improvements-in-clinical-global-impression-of-change-with-deutetrabenazine-treatment-in-tardive-dyskinesia-from-the-arm-td-and-aim-td-studies/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley